Kinase control of Latent HIV-1 Infection: PIM-1 Kinase as a Major ...
Toxoplasmosis, Malaria, and HIV: Impact of Latent Co-infection on HIV Disease
-
Upload
uc-san-diego-antiviral-research-center -
Category
Health & Medicine
-
view
508 -
download
0
description
Transcript of Toxoplasmosis, Malaria, and HIV: Impact of Latent Co-infection on HIV Disease
The UC San Diego AntiViral Research Center sponsors weekly presentations by infectious disease clinicians, physicians and researchers. The goal of these presentations is to provide the most current research, clinical practices and trends in HIV, HBV, HCV, TB and other infectious diseases of global significance. The slides from the AIDS Clinical Rounds presentation that you are about to view are intended for the educational purposes of our audience. They may not be used for other purposes without the presenter’s express permission.
AIDS CLINICAL ROUNDS
Toxoplasmosis, malaria, and HIV: Impact of latent co-infection on HIV
disease Ajay R. Bharti, MD Assistant Professor
Division of Infectious Diseases
1
Toxoplasmosis • Toxoplasma gondii • Acute infection
– Flu-like symptoms that resolve in a few weeks – CMI controls but does not eradicate the parasite – May cause congenital infection
• Latent infection – Life long – Dormant in tissue
• Brain: neurons and astrocytes • Muscle: skeletal, heart, and smooth muscle
– Reactivation disease after loss of CMI – Encephalitis and chorioretinitis
2
T. gondii Life Cycle
3
Epidemiology
4
LT Prevalence in USA
5
Increasing Prevalence with Age
6
7
LT Prevalence in France
8
9
LT and HIV Co-infection
10
Toxoplasma seroprevalence among HIV-infected patients
• Mathews, WC and Fullerton, SC • July 1, 1986 to March 31, 1990 • Laboratory database of 1599 HIV+ patients • 344 had Toxo IgG results • LT seroprevalence of 16%
Arch Pathol Lab Med. 1994 Aug;118(8):807-10. 11
LT seroprevalence among HIV+ population in southern Alberta, Canada
12
• St. Paul hospital, Addis Ababa • Tested 330 samples (165 HIV+, 165 HIV-) • Overall seroprevalence 90% • High but similar in both groups
– HIV+ (93.3%) vs. HIV- (86.7%)
13
A=31% B=68% C=28%
JPM, 1997 14
• Prospective study • Recruited 79 subjects • LT seroprevalence similar in HIV+ and HIV- • Overall prevalence of 64%
15
Impact of LT on Brain
16
Animal Studies
17
18
Morris water maze 19
Human Studies
20
• Case control study – 54 suicide attempters and 30 controls
• Self-directed violence assessed by SUAS-S score
J Clin Psy, Aug 2012 21
• Violent suicide attempts, RR=1.81 (95% CI, 1.13-2.84) • Suicide, RR=2.05 (95% CI, 0.78-5.20)
22
• First study to investigate the effect of LT in humans
• Significant delay in reaction time in those with LT
• Positive correlation between length of infection and mean reaction time
23
24
• Prospective study of 3,890 male subjects • LT increased the chance of traffic accidents
– (OR 2.43, CI95: 1.11–5.35, P = 0.027)
• RhD positivity reduced the risk of traffic accidents in LT+ subjects – (OR 0.35, CI95: 0.136–0.902, P= 0.028)
• RhD+ people are protected against LT-induced impaired reaction time
25
• 758 women in 16th week of gestation
• LT+ women had a lower body weight (p = 0.02)
• Cumulative effect
26
Other Effects of LTI
• Alzheimer’s disease • Parkinson’s disease • Schizophrenia • OCD • Increases probability of birth of male offspring • Effect on personality
– High intelligence, guilt proneness, radicalism, and high ergic tension
27
28
Mechanism behind impact of LT on brain
29
TH within cysts
PC12 cell culture 30
• Cysts widely distributed in brain • Cerebral cortex had higher cyst density than
subcortical region • Cerebellum consistently had low cysts • Myelinated fiber tracts devoid of cysts • No tropism towards dopaminergic or
hypothalamic systems
31
• Men with LT had decreased leukocyte, NK-cell and monocyte counts
• Women had increased counts • B-cell counts were reduced in both men and
women • The difference between LT+ and LT- subjects
declined with decline in Toxo IgG titers
32
Our Findings
33
Background
• Prevalence of LT is similar or higher in HIV+ compared with HIV- individuals
• ARVs do not affect LT • HIV-associated neurocognitive disorders
persist despite adequate ART – Co-infections like LT may contribute to NCI
• Impact of LT on neurocognitive impairment in HIV+ individuals has not been studied
34
Objectives
• To determine the prevalence of LT in our HIV+ cohort
• To evaluate its impact on neurocognitive functioning
35
Methods • Randomly selected 120 HIV+ participants from an NIH-
funded cohort project • Toxoplasma IgG was measured in serum by commercial
immunoassay • HNRC neurocognitive test battery was used
– Tests 7 ability areas • Performance was summarized as the validated global
deficit score (GDS) – GDS ≥ 0.5 defined neurocognitive impairment
• Data were analyzed by routine statistical methods, including Pearson’s correlations and linear regression
36
Neuropsychological Test Battery
Verbal Fluency Sound Animals Action
Attn/Working Memory PASAT-50 WMS-III Spatial Span
Processing Speed WAIS-III Digit Symbol WAIS-III Symbol Search Trails A Color Trails 1
Executive Functioning Category Test WCST-64 Color Trails II
Learning/Memory Verbal (Hopkins Verbal Learning
Test - Revised) Visual (Brief Visuospatial
Memory Test - Revised) Motor
Grooved Pegboard
37
Results
• LT was detected in 12 (10%) participants • LT+ subjects were similar to LT- subjects
except that they were significantly older • LT+ subjects were more likely to have
neurocognitive impairment (although not statistically significant) – This difference was greater among subjects who
were older than the median age of 44 years (60% vs. 33%, p = 0.11)
38
39
Results • LT was detected in 12 (10%) participants • LT+ subjects were similar to LT- subjects except that they
were significantly older • LT+ subjects were more likely to have neurocognitive
impairment (although not statistically significant) – This difference was greater among subjects who were older
than the median age of 44 years (60% vs. 33%, p = 0.11) • Among LT+ subjects, higher IgG titers titers were
associated with – higher CD4+ T-cell counts (r=0.74, p=0.05, Fig. 1) – worse GDS (r=0.31, p=0.33, Fig. 2) – On excluding the 2 outliers, worse GDS (r=0.88, p=0.0007, Fig. 2) – Higher memory deficit (p=0.01)
40
Toxo titers and CD4+ count
41
Results • LT was detected in 12 (10%) participants • LT+ subjects were similar to LT- subjects except that they
were significantly older • LT+ subjects were more likely to have neurocognitive
impairment (although not statistically significant) – This difference was greater among subjects who were older
than the median age of 44 years (60% vs. 33%, p = 0.11) • Among LT+ subjects, higher IgG titers titers were
associated with – higher CD4+ T-cell counts (r=0.74, p=0.05, Fig. 1) – worse GDS (r=0.31, p=0.33, Fig. 2) – On excluding the 2 outliers, worse GDS (r=0.88, p=0.0007, Fig. 2) – Higher memory deficit (p=0.01)
42
Toxo Titers and GDS
43
Results • LT was detected in 12 (10%) participants • LT+ subjects were similar to LT- subjects except that they
were significantly older • LT+ subjects were more likely to have neurocognitive
impairment (although not statistically significant) – This difference was greater among subjects who were older
than the median age of 44 years (60% vs. 33%, p = 0.11) • Among LT+ subjects, higher IgG titers titers were
associated with – higher CD4+ T-cell counts (r=0.74, p=0.05, Fig. 1) – worse GDS (r=0.31, p=0.33, Fig. 2) – On excluding the 2 outliers, worse GDS (r=0.88, p=0.0007, Fig. 2) – Higher memory deficit (p=0.01)
44
Conclusions
• Prevalence of LT in our HIV+ cohort was 10% – Similar to the general population (10.8%) – Not generalizable as our cohort consisted of drug
abusers
• LT+ older subjects trended towards worse neurocognitive functioning and higher anti-Toxo IgG titers were associated with worse functioning
• Studies with a larger number of LT+ individuals are needed to validate this finding
45
Future Directions
• Identify a larger HIV and LT co-infected cohort – Owen clinic and HNRC
• Investigate the impact on driving in more detail – Driving simulator studies
• Mechanistic studies – Role of inflammation: plasma and CSF – In vitro brain model
46
Malaria
47
Malaria
• Mosquito-borne infectious disease • Plasmodium spp.
– P. falciparum, P. vivax – P. ovale, P. malariae
• 300-500 million episodes of acute illness • > 1 million deaths/year worldwide
48
Life Cycle
49
Malaria and HIV Interactions
• HIV+ patients are twice as likely to get malaria* • ↑HIV RNA and ↓CD4 counts • Malaria doubles HIV-1-RNA with 0.25 log ↑** • HIV RNA ↑ (0.82 log ↑) greatest when
• Febrile patient • Parasite density >2,000/µL • CD4 >300/µL
• Mathematical model • Village of ~200,000 had excess 8,500 HIV infections and
980,000 malaria episodes*** *Patnaik et al J Infect Dis 2005; **Kublin et al Lancet 2005; ***Kublin Science 2006
50
51
Asymptomatic Malaria
• Seen in areas of high transmission • Also reported in low edemicity regions • Clinical immunity that controls parasitemia but does
not completely eliminate it • Described for both P. falciparum & P. vivax malaria • Few studies on HIV and asymptomatic malaria co-
infections • Since malaria prevalence is not homogenous, sites
need to be tested individually
52
Our Findings
53
Study Objective
• To retrospectively determine the prevalence of malaria co-infection in a cohort of HIV-infected individuals in southern India
54
Methods
• Individuals presenting to YRG CARE, Chennai, India between Jan 1, 2008 and Dec 31, 2008
• Stored serum samples randomly selected from HIV+ individuals
• Retrospectively diagnosed malaria by antibody testing and PCR
55
Results
• Malaria co-infection rate 9.8% (45/460)
• PCR negative
56
Discussion • Considerable burden of malaria co-infection • Predominently due to P. vivax • Rate of P. falciparum 6-fold higher than in the
general population • Co-infected subjects not more likely to be
immunosupressed than HIV mono-infected • Negative PCR
– Possibly due to parasitemia below detection limit – Parasite DNA degradation unlikely
• Our strategy may be used for identifying co-infections in areas with unstable malaria transmission
57
Future Directions
• Alternate site with high malaria prevalence – Nigeria
• Use of more suitable specimens – Whole blood or Dried blood spots
58
59
Acknowledgements
• United States – Scott Letendre – Davey Smith – Tom Marcotte – Ron Ellis – Connie Benson – Chip Schooley – Igor Grant – Allen McCutchan
– Cris Achim – D. J. Perkins – Walter Royal
• India – N. Kumarasamy – Jabin
• Nigeria
– Kanayo Okwuasaba – Ndidi Agala
• Funding
– NIMH 1 K23 MH085512-01A2 – CFAR International Pilot Project Grant
• Study participants
60
Questions?
61